Incidence and risk factors for developing chemotherapy-induced neuropathic pain in 500 cancer patients: A file-based observational study.
Andreas A ArgyriouJordi BrunaFoteini KalofonouRoser VelascoPantelis LitsardopoulosMontse AlemanyGarifallia G AnastopoulouHaralabos P KalofonosPublished in: Journal of the peripheral nervous system : JPNS (2024)
The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post-chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA-treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.
Keyphrases
- chemotherapy induced
- neuropathic pain
- locally advanced
- end stage renal disease
- newly diagnosed
- spinal cord
- spinal cord injury
- type diabetes
- chronic kidney disease
- ejection fraction
- cardiovascular disease
- liver failure
- prognostic factors
- squamous cell carcinoma
- risk factors
- intensive care unit
- escherichia coli
- rectal cancer
- metabolic syndrome
- drug resistant
- respiratory failure
- extracorporeal membrane oxygenation
- pseudomonas aeruginosa
- weight loss
- aortic dissection
- combination therapy
- smoking cessation
- replacement therapy